Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 8.6% – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded down 8.6% during trading on Wednesday . The stock traded as low as $19.03 and last traded at $19.03. 113,147 shares were traded during mid-day trading, a decline of 75% from the average session volume of 454,586 shares. The stock had previously closed at $20.83.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ARCT shares. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Stock Performance

The stock has a fifty day moving average of $17.63 and a 200 day moving average of $20.19. The company has a market capitalization of $487.02 million, a P/E ratio of -8.10 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the company earned ($0.61) earnings per share. Research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 15.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its holdings in shares of Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Empire Life Investments Inc. bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at about $3,498,000. XTX Topco Ltd purchased a new position in shares of Arcturus Therapeutics during the second quarter valued at about $596,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Arcturus Therapeutics in the second quarter worth about $718,000. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.